Retina

Aflibercept biosimilar candidate shows comparable efficacy in nAMD

The phase 3 MAGELLAN-AMD clinical trial for proposed biosimilar to Aflibercept (Eylea) FYB203 met its primary efficacy endpoint, demonstrating comparable efficacy between FYB203 and the reference medicine in patients with neovascular age-related macular degeneration (nAMD), according to a press release. The primary endpoint measured the change in best-corrected visual acuity...